BioMarin Pharmaceutical IncNASDAQ:BMRN
- LAST PRICE64.5006
- TODAY'S CHANGE (%)-0.5894 (-0.9055%)
- Bid / Lots64.5100/ 1
- Ask / Lots64.5500/ 1
- Open / Previous Close65.0000 / 65.0900
- Day Range
- 52 Week Range
- Volume77,076
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BMRN |
|---|---|---|
| 09:32 ET | 10843 | 64.8 |
| 09:33 ET | 1538 | 65.06 |
| 09:35 ET | 819 | 64.865 |
| 09:37 ET | 200 | 64.865 |
| 09:39 ET | 400 | 64.67 |
| 09:42 ET | 5197 | 64.6 |
| 09:44 ET | 821 | 64.67 |
| 09:46 ET | 1841 | 64.505 |
| 09:48 ET | 1168 | 64.525 |
| 09:50 ET | 3237 | 64.51 |
| 09:51 ET | 4114 | 64.51 |
| 09:53 ET | 4907 | 64.54 |
| 09:55 ET | 4154 | 64.75 |
| 09:57 ET | 2548 | 64.605 |
| 10:00 ET | 500 | 64.6899 |
| 10:02 ET | 100 | 64.66 |
| 10:04 ET | 3449 | 64.67 |
| 10:06 ET | 400 | 64.695 |
| 10:08 ET | 1606 | 64.59 |
| 10:09 ET | 1998 | 64.65 |
| 10:11 ET | 3278 | 64.5006 |
Nov 16, 2024
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO(R) (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024, from 10:45AM ET on Saturday Nov 16, 2024 by Dow Jones
10:45AM ET on Saturday Nov 16, 2024 by Dow Jones
Nov 15, 2024
DJ BioMarin Pharmaceutical Initiated at Outperform by Wolfe Research, from 5:26AM ET on Friday Nov 15, 2024 by Dow Jones
5:26AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 6, 2024
BioMarin to Participate in Three Upcoming Investor Conferences, from 8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
Oct 30, 2024
DJ BioMarin Pharmaceutical Is Maintained at Neutral by Citigroup, from 2:44PM ET on Wednesday Oct 30, 2024 by Dow Jones
2:44PM ET on Wednesday Oct 30, 2024 by Dow JonesDJ BioMarin Pharmaceutical Is Maintained at Hold by Canaccord Genuity, from 1:36PM ET on Wednesday Oct 30, 2024 by Dow Jones
1:36PM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioMarin Pharmaceutical Inc | 12.2B | 38.8x | --- |
Exact Sciences Corp | 9.8B | -52.0x | --- |
Neurocrine Biosciences Inc | 12.7B | 33.5x | +62.04% |
Medpace Holdings Inc | 10.5B | 28.9x | +35.10% |
United Therapeutics Corp | 16.6B | 16.3x | +8.22% |
Qiagen NV | 9.5B | 105.9x | +12.66% |
Company Information
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Contact Information
- Headquarters
- 105 Digital DriveNOVATO, CA, United States 94949
- Phone
- 415-505-6700
- Fax
- 415-382-7889
Executives
- Non-Executive Independent Chairman of the Board
- Richard Meier
- President, Chief Executive Officer, Director
- Alexander Hardy
- Chief Financial Officer, Executive Vice President - Finance
- Brian Mueller
- President - Worldwide Research and Development
- Henry Fuchs
- Executive Vice President - Global Manufacturing and Technical Operations, Chief Technical Officer
- C. Greg Guyer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $12.2B |
|---|---|
Revenue (TTM) | $2.8B |
Shares Outstanding | 190.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.29 |
EPS | $1.66 |
Book Value | $26.25 |
P/E Ratio | 38.8x |
Price/Sales (TTM) | 4.4 |
Price/Cash Flow (TTM) | 29.0x |
Operating Margin | 11.81% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
